Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study. (December 2017)

• Record Type: Journal Article
• Authors: Mulu, Wondemagegn; Abera, Bayeh; Yimer, Mulat; Hailu, Tadesse; Ayele, Haimanot; Abate, Dereje
• Is Part Of: BMC research notes. Volume 10:Number 1(2017)
• Page Start: 1
• Page End: 8
• Publication Date: 2017-12
• Subjects: M. tuberculosis -- Rifampicin -- Resistance -- Gene Xpert MTB/RIF -- Ethiopia; Medicine -- Periodicals; Biology -- Periodicals; 610.5
• DOI: 10.1186/s13104-016-2328-4
• Languages: English
• ISSNs: 1756-0500

Abstract

Abstract Background Prevailing data on rifampicin-resistantM. tuberculosis is essential for early management of MDR-TB. Therefore, this study was conducted to determine the prevalence of rifampicin-resistantMycobacterium tuberculosis and associated factors among presumptive TB cases in Debre Markos Referral Hospital, Ethiopia. Methods A cross-sectional study was conducted from September 2014 to March 2015. Detection ofM. tuberculosis and resistance to rifampicin was performed using Gene Xpert MTB/RIF assay. Data was collected using structured questionnaire by face to face interview. Logistic regression analysis was computed to determine the associated factors of rifampicin-resistantM. tuberculosis . Results A total of 505 presumptive TB patients included in the study. The prevalence ofM. tuberculosis confirmed cases was 117 (23.2%) (95% CI 19.7–27%). It was higher among males (27.9%) than females (17.9%) (AOR: 2.17; CI 1.35–3.49). Of the 117M. tuberculosis confirmed cases, 12 (10.3%) (95% CI 6.0–17.1%) were resistant to rifampicin. Rifampicin-resistantM. tuberculosis was noticed in 7 previously treated TB patients (17.1%) and 5 treatment naive patients (6.7%) (AOR: 4.16; CI 1.04–16.63). The prevalence of rifampicin-resistantM. tuberculosis was 6 (9.8%) and 6 (11.3%) in pulmonary and extra-pulmonary infections, respectively. Of the 30, MTB/HIV co-infection, 3 (10%) were rifampicin-resistantM. tuberculosis . Conclusion Rifampicin-resistantM. tuberculosis is prevalent in both pulmonary and extra-pulmonary tuberculosis patients. Previous treatment with anti-TB drugs was significantly associated with rifampicin resistance. Therefore, the use of Gene Xpert should be scaled up across the country for rapid detection and management of drug resistantM. tuberculosis .